Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity

a technology of benzothiazepines and pyrrolol, which is applied in the direction of biocide, organic chemistry, drug compositions, etc., can solve the problems of inferior general potency, unsatisfactory need for antipsychotic agents with substantial therapeutic activity, and limited therapeutic use, so as to reduce the dose needed, prolong the exposure to the drug, and reduce the effect of toxicity and accumulation

Inactive Publication Date: 2002-01-17
SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

0047] As documented in the experimental part, the "atypicity" of the neuroleptic action of formula (I) derivatives makes it possible to treat the above-mentioned pathologies effectively, at the same time reducing to a minimum the extrapyramidal side effects normally associated with the classic antipsychotic agents. The substantial receptor activity that

Problems solved by technology

Unfortunately, the occurrence of cases of agranulocytosis has limited the therapeutic use of this drug (Lancet.
The (R) isomer presents a more "atypical" profile, with fewer side effects, b

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity
  • Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity
  • Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0099] (.+-.)-9-(4-methylpiperazin-1-yl)-9,10-dihydropyrrolo[2,1-b][1,3]en-zo-thiazepine (3a)

[0100] A mixture of 25a (0.65 g, 2.0 mmol) and N-methylpiperazine (1.1 ml, 10.0 mmol) was heated to 130.degree. C. for 2 hours under argon, cooled, poured onto crushed ice and extracted with ethyl ether. The organic extracts collected were washed with brine, anhydrified. and concentrated. The residue was chromatographed (EtOAc) to give 0.45 g (75% yield) of 3a as colourless prisms: melting point 206-207.degree. C. (hexane); .sup.1H NMR (CDCl.sub.3) .delta.7.49-7.09 (m, 4H); 6.87 (m, 1H), 6.29 (m, 1H), 4.68 (dd, 1H, J=14.4, 8.6 Hz), 4.51 (dd 1H, J=14.4, 3.7 Hz), 2.56-2.34 (m, 8H), 2.23 (s, 3H); .sup.13C NMR (CDCl.sub.3) .delta.138.1, 134.6, 132.9, 130.4, 127.3, 126.9, 123.9, 121.7, 113.3, 107.7, 66.1, 55.9, 48.8, 46.6. 46.1. MS m / z 299 (100, M.sup.+), 219, 200, 167, 149, 113. Anal. (C.sub.17H.sub.21N.sub.3S) C, H, N.

example 2

[0101] (.+-.)-7-chloro9-(4-methylpiperazin-1-yl)-9,10-dihydropyrrolo[2,1-b-][1,3]benzothiazepine (3b) (ST1455)

[0102] The titre compound was obtained starting from 25b (0.3 g, 0.95 mmol) using the procedure described above. 3b was obtained as colourless prisms (68% yield): melting point 210-211.degree. C. (hexane); .sup.1H NMR (CDCl.sub.3) .delta.7.51 (d, 1H, J=2.4 Hz); 7.30 (d, 1H, J=8.5 Hz), 7.06 (dd, 1H, J=8.5, 2.4 Hz), 6.86 (m, 1H), 6.29 (m, 1H), 6.05 (m, 1H), 4.71 (dd, 1H, J=14.0, 8.6 Hz), 4.45 (dd, 1H, J=14.0, 3.4 Hz), 3.95 (dd, 1H, J=8.6, 3.4 Hz), 2.65-2.25 (m, 8H), 1.42 (s, 3H); .sup.13C NMR (CDCl.sub.3) .delta.140.1, 133.2, 133.0, 132.4, 131.6, 127.3, 123.9, 121.1, 113.6, 107.9, 65.9, 55.8, 55.7, 47.7, 45.9, 44.9, 26.8. MS m / z 333 (10, M.sup.+), 250, 233 (100), 201, 166, 139. Anal. (C.sub.17H.sub.20CIN.sub.3S): C, H, N. The dihydrochloride salt (named hereinafter ST1468) was obtained by dissolving an analytical sample in HCl 1N in methanol. The solvent was evaporated and the...

example 3

[0103] Semipreparatory Chiral Separation of (.+-.)-3b

[0104] First of all, the hydrochloride salt of (.+-.)-3b was purified on a short column filled with silica gel, using dichloromethane and methanol (9:1) as the eluent. The purified solvent was converted to the free base. Evaporation of the solvent gave an oily residue which was dissolved in isopropanol and the solution was diluted with hexane until the 95:5 ratio was obtained. For the separation of the enantiomers, a 10-15 mg / ml concentration of the racemic mixture was made. A mixture of hexane (plus 0.1% triethylamide) and isopropanol was used as the mobile phase.

[0105] A gradient-type mixer maintained the ratio between the solvents hexane and isopropanol at 95:5. Injection amounts were 100 .mu.l per injection. The enantiomers were collected using a fraction collector. Only fractions with a signal above 10% (10 mV) of the total scale were collected. The amounts with signals below 10% were collected separately and used for a secon...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to view more

Abstract

Polycondensated heterocycles with a pyrrole[2,1-b][1,3]benzothiazepine structure of the following formula (I) where the groups are defined as in the description are disclosed. As compared to known antipsychotic agents, these compounds present substantial activity associated with a simultaneous reduction in unwanted extrapyramidal symptoms. These compounds can be formulated in pharmaceutical compositions for the treatment of psychoses such as, for example, schizophrenia.

Description

[0001] The present invention relates to the field of antipsychotic drugs, in particular to polycondensated heterocycles with a pyrrolo[2, 1-b][1,3]benzothiazepine structure.STATE OF THE ART[0002] The intervention of dopamine and dopaminergic neurons in the pathology of a variety of psychiatric and neurological disorders has been amply documented (Caine, D. B., Therapeutics and Neurology; Blackwell Scientific Publications, Oxford 1980, p. 281). In addition, it is also known that drugs which are active on dopamine receptors may play an important role in the therapy of such disorders; there is therefore considerable interest in the effects of dopamine agonist and antagonist compounds on dopaminergic is receptors, particularly with a view to their therapeutic implications.[0003] Chlorpromazine and aloperidol have long been the treatment of choice for acute and chronic schizophrenia. It has been postulated that these drugs relieve the positive symptoms of the disease by blocking dopamine...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/00A61K31/554A61K45/00A61K47/00A61P25/00A61P25/18A61P25/22A61P25/24A61P25/28C07D513/04
CPCC07D513/04A61P25/00A61P25/18A61P25/22A61P25/24A61P25/28A61P43/00
Inventor CAMPIANI, GIUSEPPENACCI, VITOMINETTI, PATRIZIACESARE, MARIA ASSUNTA DI
Owner SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap